Institut Jules Bordet Collaborates with OncoDNA to Explore Biology of Brain Metastases Using Personalized Liquid Biopsy From Cerebrospinal Fluid

June 17th 2021


OncoDNA, a theranostic and genomic company specializing in precision medicine, and the Institut Jules Bordet, a hospital and research institute of excellence specializing in oncology, are pleased to announce their collaboration as part of an international, multicentre prospective interventional study aiming to better understand the biology of central nervous system (CNS) metastases. Sponsored by the Institut Jules Bordet within the Oncodistinct Network the BrainStorm study will enroll a total of 600 patients newly diagnosed with solid tumors in a dozen collaborating sites in France and Belgium and Luxembourg. The genomic and clinical data from the study will be used to build a large clinico pathological database for CNS metastases including circulating-tumor DNA (ctDNA) analyzes from cerebrospinal fluid (CSF) samples. Please discover the press release here.